Table 1.

Baseline and terminal characteristics of study groups.

	Sham—vehicle n = 10	LAD—vehicle n = 12	LAD—captopril n = 12
Body weight, onset of treatment (day 7) (g)	22.2 ± 0.3	22.6 ± 0.3	22.1 ± 0.2
Heart rate, day 7 (BMP)	488 ± 19	525 ± 12	515 ± 12
Daily water intake (g/day)	7.5 ± 0.2	7.2 ± 0.1	7.2 ± 0.1
Captopril dose (mg/kg/day)	-	-	640 ± 16
Body weight, termination (g)	22.6 ± 0.3	23.1 ± 0.3	22.4 ± 0.3 #
Heart weight, termination (mg)	134 ± 4	159 ± 6 **	138 ± 6 #
Heart weight ratio to tibia length, termination	7.7 ± 0.2	9.1 ± 0.4 *	7.8 ± 0.3 #
Heart rate, week 5 (BPM)	442 ± 18	484 ± 8	464 ± 16
LV chamber volume (mm)	38.5 ± 4.2	69.4 ± 4.7 ***	72.9 ± 5.1

Body weight and echocardiography derived heart rate measured at the onset of treatment (day 7) and/or termination. Heart weight was measured after tissue clearing for light sheet imaging. End-diastolic LV chamber volume was estimated on parasternal long axis view at the time of termination. Data is mean ± s.e.m. One-way ANOVA with Tukey’s post hoc test. **p < 0.01 ***p < 0.001 vs sham—vehicle, #p < 0.05 vs LAD—vehicle.